Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS)

Lupus

Volumn 22, Issue 13, 2013, Pages 1327-1335

  Agmon Levin, N ^a   Rosario C ^a,b   Katz, B S Porat ^c   Zandman Goddard, G ^a   Meroni, P ^d   Cervera, R ^e   Stojanovich, L ^f   Blank, M ^a   Pierangeli, S S ^g   Praprotnik, S ^h   De Meis, E ⁱ   Seguro, L Parente ^j   Ruffatti, A ^k   Pengo, V ^l   Tincani, A ^m   Doria, A ^k   Shoenfeld, Y ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Hospital de Pedro Hispano   (Portugal)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d UNIVERSITY OF MILAN   (Italy)

^e HOSPITAL CLÍNIC   (Spain)

^f Bezhanijska Kosa University Medical Center   (Serbia)

^g University of Texas Medical Branch School of Medicine   (United States)

^h UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

ⁱ INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^j UNIVERSITY OF SÃO PAULO   (Brazil)

^k UNIVERSITY OF PADOVA   (Italy)

^l UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^m UNIVERSITY OF BRESCIA   (Italy)

more..

Author keywords

anti cardiolipin; antiphospholipid syndrome; autoimmunity; catastrophic antiphospholipid syndrome; CMV; Ferritin; hyperferritinemia

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; CYTOMEGALOVIRUS ANTIBODY; FERRITIN; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; RUBELLA ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERFERRITINEMIA; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEROLOGY; TERMINAL DISEASE; VEIN THROMBOSIS;

ANTI-CARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CMV; FERRITIN; HYPERFERRITINEMIA;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODIES, PROTOZOAN; ANTIBODIES, VIRAL; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CATASTROPHIC ILLNESS; FEMALE; FERRITINS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SEROLOGIC TESTS; UP-REGULATION;

EID: 84887105122     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313504633     Document Type: Article

References (68)

1. Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. Blood Rev. 2009 ; 23: 95-104
2. Harrison PM, Arosio P. The ferritins: Molecular properties, iron storage function and cellular regulation. Biochim biophys Acta. 1996 ; 1275: 161-203
3. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002 ; 99: 3505-3516
4. Kondo T, Shirasawa T, Itoyama Y, Mori H. Embryonic genes expressed in Alzheimer's disease brains. Neurosci Lett. 1996 ; 209: 157-160
5. Linert W, Jameson GN. Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's disease. J Inorg Biochem. 2000 ; 79: 319-326
6. Weinstein RE, Bond BH, Silberberg BK. Tissue ferritin concentration in carcinoma of the breast. Cancer. 1982 ; 50: 2406-2409
7. Recalcati S, Invernizzi P, Arosio P, Cairo G. New functions for an iron storage protein: The role of ferritin in immunity and autoimmunity. J Autoimmun. 2008 ; 30: 84-89
8. Broxmeyer HE, Bognacki J, Dorner MH, de Sousa M. Identification of leukemia-associated inhibitory activity as acidic isoferritins. A regulatory role for acidic isoferritins in the production of granulocytes and macrophages. J Exp Med. 1981 ; 153: 1426-1444
9. Hann HW, Stahlhut MW, Lee S, London WT, Hann RS. Effects of isoferritins on human granulocytes. Cancer. 1989 ; 63: 2492-2496
10. Morikawa K, Oseko F, Morikawa S. H- and L-rich ferritins suppress antibody production, but not proliferation, of human B lymphocytes in vitro. Blood. 1994 ; 83: 737-743
11. Atteritano M, David A, Bagnato G, et al. Haemophagocytic syndrome in rheumatic patients. A systematic review. Eur Rev Med Pharmacol Sci. 2012 ; 16: 1414-1424
12. Uppal SS, Al-Mutairi M, Hayat S, Abraham M, Malaviya A. Ten years of clinical experience with adult onset Still's disease: Is the outcome improving?. Clin Rheumatol. 2007 ; 26: 1055-1060
13. Orbach H, Zandman-Goddard G, Amital H, et al. Novel biomarkers in autoimmune diseases: Prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci. 2007 ; 1109: 385-400
14. Blake DR, Bacon PA, Eastham EJ, Brigham K. Synovial fluid ferritin in rheumatoid arthritis. BMJ. 1980 ; 281: 715-716
15. Yildirim K, Karatay S, Melikoglu MA, Gureser G, Ugur M, Senel K. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci. 2004 ; 34: 423-426
16. Sfagos C, Makis AC, Chaidos A, et al. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. Mult Scler. 2005 ; 11: 272-275
17. Da Costa R, Szyper-Kravitz M, Szekanecz Z, et al. Ferritin and prolactin levels in multiple sclerosis. Isr Med Assoc J. 2011 ; 13: 91-95
18. Beyan E, Beyan C, Demirezer A, Ertugrul E, Uzuner A. The relationship between serum ferritin levels and disease activity in systemic lupus erythematosus. Scand J Rheumatol. 2003 ; 32: 225-228
19. Lim MK, Lee CK, Ju YS, et al. Serum ferritin as a serologic marker of activity in systemic lupus erythematosus. Rheumatol Int. 2001 ; 20: 89-93
20. Zandman-Goddard G, Orbach H, Agmon-Levin N, et al. Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients. Clin Rev Allergy Immunol. 2011 ; 44: 23-30
21. Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev. 2007 ; 6: 457-463
22. Mewar D, Moore DJ, Young-Min S, et al. Antiferritin antibodies discovered by phage display expression cloning are associated with radiographic damage in rheumatoid arthritis. Arthritis Rheum. 2005 ; 52: 3868-3872
23. Baerlecken NT, Linnemann A, Gross WL, et al. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis. 2012 ; 71: 943-947
24. Pierangeli SS, Chen PP, Raschi E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenic mechanisms. Semin Thromb Hemost. 2008 ; 34: 236-250
25. Comarmond C, Cacoub P. Antiphospholipid syndrome: From pathogenesis to novel immunomodulatory therapies. Autoimmun Rev. 2013 ; 12: 752-757
26. Shoenfeld Y. APS - more systemic disease than SLE. Clin Rev Allergy Immunol. 2007 ; 32: 129-130
27. Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2010 ; 12: 70-76
28. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4: 295-306
29. Agmon-Levin N, Kivity S, Tzioufas AG. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren's syndrome. J Autoimmun. 2012 ; 39: 234-239
30. de Carvalho JF, Pereira RM, Shoenfeld Y. The mosaic of autoimmunity: The role of environmental factors. Front Biosci (Elite Ed). 2009 ; 1: 501-509
31. Blank M, Asherson RA, Cervera R, Shoenfeld Y. Antiphospholipid syndrome infectious origin. J Clin Immunol. 2004 ; 24: 12-23
32. de Carvalho JF, Pereira RM, Shoenfeld Y. Current knowledge regarding Asherson's syndrome. Expert Rev Clin Immunol. 2009 ; 5: 587-591
33. Ruddell RG, Hoang-Le D, Barwood JM, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology. 2009 ; 49: 887-900
34. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. Hyperferritinemic syndrome: Macrophage activation syndrome, Still's disease, septic shock, catastrophic APS and anti-CD28 therapy. BMC Med. 2013 ; 11: 185-185
35. Agmon-Levin N, Blank M, Zandman-Goddard G, et al. Vitamin D: An instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. 2011 ; 70: 145-150
36. Ortega-Hernandez OD, Agmon-Levin N, Blank M, Asherson RA, Shoenfeld Y. The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: Compelling evidence. J Autoimmun. 2009 ; 32: 1-6
37. Toubi E, Shoenfeld Y. Livedo reticularis as a criterion for antiphospholipid syndrome. Clin Rev Allergy Immunol. 2007 ; 32: 138-144
38. Matsuura E, Lopez LR. Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis?. Clin Dev Immunol. 2004 ; 11: 103-111
39. Soltesz P, Szekanecz Z, Kiss E, Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev. 2007 ; 6: 379-386
40. George D, Erkan D. Antiphospholipid syndrome. Prog Cardiovasc Dis. 2009 ; 52: 115-125
41. Pang JH, Jiang MJ, Chen Y, et al. Increased ferritin gene expression in atherosclerotic lesions. J Clin Invest. 1996 ; 97: 2204-2212
42. Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus. 2006 ; 15: 191-197
43. Sanna G, D'Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am. 2006 ; 32: 465-490
44. Cheepsunthorn P, Palmer C, Menzies S, Roberts RL, Connor JR. Hypoxic/ischemic insult alters ferritin expression and myelination in neonatal rat brains. Journal Comp Neurol. 2001 ; 431: 382-396
45. Qi Y, Dawson G. Hypoxia specifically and reversibly induces the synthesis of ferritin in oligodendrocytes and human oligodendrogliomas. J Neurochem. 1994 ; 6: 1485-1490
46. Qi Y, Jamindar TM, Dawson G. Hypoxia alters iron homeostasis and induces ferritin synthesis in oligodendrocytes. J Neurochem. 1995 ; 64: 2458-2464
47. Gorter JA, Mesquita AR, van Vliet EA, da Silva FH, Aronica E. Increased expression of ferritin, an iron-storage protein, in specific regions of the parahippocampal cortex of epileptic rats. Epilepsia. 2005 ; 46: 1371-1379
48. Hendriksen H, Datson NA, Ghijsen WE, et al. Altered hippocampal gene expression prior to the onset of spontaneous seizures in the rat post-status epilepticus model. Eur J Neurosci. 2001 ; 14: 1475-1484
49. Tanne D, Hassin-Baer S. Neurologic manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep. 2001 ; 3: 286-292
50. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity - friends or foes?. Trends Immunol. 2009 ; 30: 409-414
51. Asherson RA, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome - molecular mimicry?. J Rheumatol. 2000 ; 27: 12-14
52. Blank M, Eisentin M, Asherson RA, Cervera R, Shoenfeld Y Infection and autoimmunity. Rose YSNR, ed. Amsterdam: Elsevier ; 2004: 473-490.
53. Cervera R, Bucciarelli S, Espinosa G, et al. Catastrophic antiphospholipid syndrome: Lessons from the "CAPS Registry" - a tribute to the late Josep Font. Ann N Y Acad Sci. 2007 ; 1108: 448-456
54. Cruz-Tapias P, Blank M, Anaya JM, Shoenfeld Y. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol. 2012 ; 24: 389-393
55. Espinosa G, Bucciarelli S, Asherson RA, Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: Pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost. 2008 ; 34: 290-294
56. Shoenfeld Y, Blank M, Krause I. The relationship of antiphospholipid antibodies to infections - do they bind to infecting agents or may they even be induced by them?. Clin Exp Rheumatol. 2000 ; 18: 431-432
57. Barzilai O, Sherer Y, Ram M, Izhaky D, Anaya JM, Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: Are they truly notorious? A preliminary report. Ann N Y Acad Sci. 2007 ; 1108: 567-577
58. Hojnik M, Gilburd B, Ziporen L, et al. Anticardiolipin antibodies in infections are heterogenous in their dependency on beta 2-glycoprotein I: Analysis of anticardiolipin antibodies in leprosy. Lupus. 1994 ; 3: 515-521
59. Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev. 2008 ; 8: 116-120
60. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum. 2002 ; 31: 256-263
61. Zinger H, Sherer Y, Goddard G, et al. Common infectious agents prevalence in antiphospholipid syndrome. Lupus. 2009 ; 18: 1149-1153
62. Arnson Y, Amital H, Guiducci S, et al. The role of infections in the immunopathogensis of systemic sclerosis - evidence from serological studies. Ann N Y Acad Sci. 2009 ; 1173: 627-632
63. Criscuoli V, Rizzuto MR, Cottone M. Cytomegalovirus and inflammatory bowel disease: Is there a link?. World J Gastroenterol. 2006 ; 12: 4813-4818
64. Filippi C, von Herrath M. How viral infections affect the autoimmune process leading to type 1 diabetes. Cell Immunol. 2005 ; 233: 125-132
65. Sekigawa I, Nawata M, Seta N, Yamada M, Iida N, Hashimoto H. Cytomegalovirus infection in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2002 ; 20: 559-564
66. Garcia PC, Longhi F, Branco RG, Piva JP, Lacks D, Tasker RC. Ferritin levels in children with severe sepsis and septic shock. Acta paediatr. 2007 ; 96: 1829-1831
67. Moller HJ, Moestrup SK, Weis N, et al. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Crit Care Med. 2006 ; 34: 2561-2566
68. Patteril MV, Davey-Quinn AP, Gedney JA, Murdoch SD, Bellamy MC. Functional iron deficiency, infection and systemic inflammatory response syndrome in critical illness. Anaesth Intensive Care. 2001 ; 29: 473-478